Interrupting my usual #MedTwitter posts to mark 3.11.2023 as best day of my life ❤️

I support David’s conclusion. Majority of patients with large B-cell lymphoma should no longer get HDMTX for CNS prophy and definitely not intercalated with their essential first line regimen Hope we can get payer coverage for ctDNA testing on CSF soon #lymsm

#EHA2026 #AML #leusm Dr. Barote: OPTI-AML: the first prospective RCT of Ven 14d vs 28d Aza ×2 cycles in older AML — and it reframes the whole “shorter is fine” debate. AV14 did NOT meet non-inferiority for CR (43% vs 49% AV28; ΔCI –8% to 21%, upper bound >10%). Key takeaways 👇🏽 But the real story is molecular, not calendar: • NPM1 & IDH1/2 → favored 28d (61% vs 42%) • Every other subset → 44% vs 44%, identical And cumulative delivery, not the planned schedule, tracked with response: pts who couldn’t complete Ven had lower CR in BOTH arms (AV28 39% vs 56%; AV14 36% vs 49%). Only 68% of AV28 finished C1 Ven (vs 89%) — mostly infections. MRD negativity (78% vs 77%) and toxicity were superimposable. OS numerically favored AV28 but on MVA was driven by TP53/KRAS counts, not arm. Bottom line: Ven duration should be titrated to molecular subtype triplet partner — what matters is cumulative exposure delivered, and for NPM1/IDH that exposure still earns its keep. #EHA2026 #EHA26

As #celltherapy physicians it is critical we expand our practice and programs to include these novel therapies in more aggressive diseases with high unmet need . My clinic now has autoimmune , melanoma (getting CARs and TILs) and hopefully others in the near future #ASCO25

Our @OUdoim @StephensonCC current and former fellows are ⭐️s @Noha_Soror is a #CARtcell research mentor to so many fellows residents and students here

Outstanding results and speed does matter a lot here -> TIME LIMITED BITE Dara frontline study ? (Frontline CAR is probably too toxic as seen already). Let’s at least try and lose the Cytoxan esp in GI AL, & what about ASCT? @Abdallah81MD @HadidiSamer @Papa_Heme @msalmanfaisal

Important message especially to our fellows and junior faculty, we have to have a broad understanding of our field before we decide to “sub-specialize” , I support this message even though my practice is similar with mostly myeloma, lymphoma. allos/autos and CARs (now TILs too)

Don’t miss the opportunity to present your research at the premier meeting in hematologic malignancies. The abstract submission deadline for #SOHO2026 is May 15 at 11:59 PM CST. Submit your abstract today at soho.click/abstracts . @SocietyofHemOnc

Proud of our @OUCollegeofMed M4 and future oncologist Anusha Gopalam for publishing this work on disseminated adenovirus in patients with lymphoma following #CARtcell @JosephSassineMD @OUdoim @StephensonCC #CORDS lab pubmed.ncbi.nlm.nih.gov/4192…

OpenEvidence the GOAT. Still making some errors but it is getting better exponentially. No need for knowledge experts in future if you know what questions to ask. Good clinical skills and judgement will be needed not brut medical knowledge.

Late outcomes after posttransplant cyclophosphamide–based GVHD prophylaxis in patients with AML: an ALWP-EBMT study @BloodPortfolio @Bloodneoplasia

Truly grateful to my mentors at @StephensonCC & @OUCollegeofMed , as well as mentors beyond our organization, and to all of my research and academic collaborators who helped me reach this milestone of promotion to Associate Professor. Feeling a little older, and a little wiser

Important data to be aware of. Hard to say what’s driving the late malignancies signal but more reasons to move away from old cytotoxic therapies at least in the frontline tx (hoping BITEs & even potentially future #CARtcell would be safer options)#lymsm congrats to the authors

We have one of the best HemOnc fellowship programs in the nation at @StephensonCC, and the most supportive leaders! It’s a privilege to be here ✨ #ThankAResidentDay

Really excited about these updates to ChiefBrief

Good luck Dr @NausheenAhmedMD I have no doubt you’ll accomplish many great things